newsfilter
← Latest News
GlobeNewswire·

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:N